SecurityVALE.P / Vale S.A. Preferred Class A Shares ADR (91912E204)
Institutional Owners15
Institutional Shares110,345,133
Institutional Value$ 857,466,000 USD
Related 91911TAG8 / Vale Overseas 6.25% Notes 1/23/17
91911TAH6 / Vale Overseas 6.875% Notes 11/21/36
91911TAM5 / Vale Overseas Limited 4.375% 01/11/22
91911TAL7 / Vale Overseas Limited 4.625% Guaranteed Notes 09/15/20
91911TAJ2 / Vale Overseas Limited 5.625% Guaranteed Notes 09/15/2019
91911TAF0 / Vale Overseas Limited 6.250 Guaranteed Notes 1/11/2016
91911TAK9 / Vale Overseas Limited 6.875% Guaranteed Notes 11/10/39
91911TAD5 / Vale Overseas Limited 9.0% Guaranteed Notes 0/15/13
91911TAE3 / Vale Overseas Ltd 8.25% Notes 01/17/2034
VALE / Vale S.A.
91912EAA3 / Vale Sa 5.625% 09/11/42

Institutional Stock Ownership and Shareholders()

VALE.P / Vale S.A. Preferred Class A Shares ADR Institutional Ownership

Vale S.A. Preferred Class A Shares ADR (NYSE:VALE.P) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 110,345,133 shares. Largest shareholders include BlackRock Group LTD, Aberdeen Asset Management Plc/uk, Causeway Capital Management Llc, BlackRock Fund Advisors, Group One Trading, L.p., BlackRock Investment Management, LLC, BlackRock Advisors LLC, Capital Markets Trading Uk Llp, Westwood Global Investments, LLC, and Capstone Asset Management Co.
Vale S.A. Preferred Class A Shares ADR (NYSE:VALE.P) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/vale.p"><img src="https://images.fintel.io/us-vale.p-so.png" alt="VALE.P / Vale S.A. Preferred Class A Shares ADR Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Westwood Global Investments, LLC 472,826 472,826 0.00 5,783 6,014 3.99
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 803 1,074 33.75 69 136 97.10
2018-05-11 13F-HR ADVENT CAPITAL MANAGEMENT /DE/ Call 1,700 0 -100.00 52 0 -100.00
2017-08-08 13F-HR Airain ltd 787,174 68,978 -91.24 7,069 562 -92.05
2018-05-01 13F-HR COMMERZBANK AKTIENGESELLSCHAFT /FI Call 23,000 0 -100.00 281 0 -100.00
2017-02-10 13F-HR BlackRock Group LTD 46,729,583 59,005,728 26.27 220,097 406,551 84.71
2018-05-14 13F-HR IHT Wealth Management, LLC 253 0 -100.00 3 0 -100.00
2018-04-30 13F-HR Price Capital Management, Inc. 270,661 0 -100.00 3,310 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 508,876 633,638 24.52 2,397 4,366 82.14
2018-05-15 13F-HR Capital Markets Trading Uk Llp Call 218,000 516,000 136.70 2,666 6,564 146.21
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 804,100 884,800 10.04 9,834 11,255 14.45
2017-02-10 13F-HR BlackRock Fund Advisors 5,147,496 5,373,932 4.40 24,245 37,026 52.72
2018-05-14 13F-HR Poehling Capital Management, Llc 1,100 600 -45.45 13 8 -38.46
2016-11-14 13F-HR Edmond de Rothschild (Europe) 10,000 10,000 0.00 40 47 17.50
2017-07-10 13F-HR CAPSTONE ASSET MANAGEMENT CO 234,036 221,716 -5.26 2,102 1,807 -14.03
2017-02-10 13F-HR BlackRock Investment Management, LLC 600,000 783,000 30.50 2,826 5,395 90.91
2018-05-15 13F-HR CAUSEWAY CAPITAL MANAGEMENT LLC 6,529,849 8,517,774 30.44 79,860 108,346 35.67
2018-07-17 13F-HR Calamos Advisors LLC Call 337,500 0 -100.00 4,293 0 -100.00
2017-08-10 13F-HR ABERDEEN ASSET MANAGEMENT PLC/UK 35,657,790 35,256,941 -1.12 320,207 287,344 -10.26
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 342,664 0 -100.00 1,614 0
2018-04-06 13F-HR Eqis Capital Management, Inc. 77,482 0 -100.00 948 0 -100.00
2018-05-01 13F-HR SUMMIT SECURITIES GROUP, LLC 239,700 0 -100.00 2,932 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co Call 648,200 120,000 -81.49 7,927 1,526 -80.75
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 3,084 0 -100.00 120 0 -100.00

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 91912E204